Progress in the modification of conventional coronary risk factors and lifestyle behavior has reduced the incidence of atherosclerotic coronary artery disease; nonetheless, it continues to be the leading cause of mortality in the world. This might be attributed to the defective risk stratifying and prevention strategy for coronary artery disease. In the current clinical setting, atherosclerotic coronary artery disease risk is estimated on the basis of identifying and quantifying only traditional risk factors; it does not take into consideration nontraditional risk factors. In addition, most of the prevailing therapies for atherosclerosis are targeted toward traditional risk factors rather than atherosclerosis itself. It is desirable to develop a method that can directly assess the activity of atherogenesis at every moment. Endothelial function is an integrated index of all atherogenic and atheroprotective factors present in an individual including nontraditional factors and heretofore unknown factors, and it is reported to have additional predictive value for future cardiovascular events to traditional risk factors. Moreover, endothelial function has a pivotal role in all phases of atherosclerosis, from initiation to atherothrombotic complication, and is reversible at every phase, indicating that endothelial function-guided therapies might be effective and feasible in cardiovascular practice. Thus, the introduction of endothelial function testing into clinical practice might enable us to innovate individualized cardiovascular medicine. In this review, we summarize the current knowledge on the contribution of endothelial dysfunction to atherogenesis and review the methods that assess endothelial function. Finally, we focus on the effects of major antiatherosclerotic disease therapies on endothelial function and argue the possibility of noninvasive assessment of endothelial function aiming at individualized cardiovascular medicine. Coron Artery Dis 25:713-724
Introduction
The vascular endothelium is an active monolayer of cells lining the entire circulatory system, from the heart to the smallest capillaries, separating the vascular wall from circulating blood (Fig. 1a) , and it plays an essential role in almost all basic biological vascular functions in health and disease [1, 2] . The endothelium not only serves as a nonadhesive and highly selective physical barrier to control the vascular permeability, it also releases a large number of vasoactive substances to regulate the vascular tone and the remodeling of the vessel wall ( Fig. 1b) [2] . Endothelium-derived relaxing factors include nitric oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing factors. There are also important endotheliumderived constricting factors including endothelin-1 [3] . Cardiovascular risk factors, which include traditional, nontraditional, and heretofore unknown factors, have the potential to impair endothelial function through various complex mechanisms and lead to unfavorable physiological vascular changes such as vasomotor tone alterations, thrombotic dysfunctions, smooth muscle cell proliferation and migration, and leukocyte adhesion and migration [2] . Overproduction of reactive oxygen species (ROS) and increased oxidative stress may serve as a common pathogenic mechanism for the effect of these risk factors [2] . In addition to various systemic risk factors, as shown in Table 1 , local factors, including balloon angioplasty and hemodynamic forces such as shear stress, have been suggested as important modulators of endothelial function [4, 5] .
In the current clinical settings, the risk for atherosclerotic cardiovascular disease is estimated on the basis of identifying and quantifying the traditional risk factors [6] . For example, the Pooled Cohort Equation for 10-year atherosclerotic cardiovascular disease risk is calculated with seven variables [6] , although numerous other factors are suggested to be associated with atherogenesis and endothelial dysfunction (Table 1) . Many individuals with coronary artery disease have only one or none of the traditional risk factors [7] , and traditional risk factors might account for only half of the pathogeneses of atherosclerotic diseases [1] , indicating that nontraditional and unknown risk factors have a substantial role in atherogenesis. Thus, the current patient-specific risk assessment may be insufficient to identify individual risk. In addition, most of the prevailing therapies for atherosclerosis are targeted at traditional risk factors, not for atherosclerosis itself. It has been expectantly desired to develop a methodology that can directly assess the condition of atherogenesis at every moment. Endothelial function is an integrated index of all atherogenic and atheroprotective factors present in an individual, and thus it predicts cardiovascular events independent from traditional risk factors [8] [9] [10] [11] . Furthermore, endothelial function might be reversible at every phase of atherosclerosis and has a pivotal role in all phases, from initiation to atherothrombotic complication [12] [13] [14] . Taken together, a strategy based on endothelial function assessment is possibly a proper approach and will lead to the development of more tailored medicine.
In the current review, we present available data on the contribution of endothelial dysfunction to atherogenesis and review the methods that assess endothelial function. Finally, we focus on the effects of major antiatherosclerotic therapies on endothelial function and argue the Anatomy and functions of normal endothelium. (a) The vascular endothelium is a monolayer of cells forming an interface between the vessel lumen and the vascular smooth muscle cells. The endothelium is a dynamic autocrine and paracrine organ. (b) Through its capacity to sense and respond to mechanical and biochemical stimuli, the endothelium plays an active and critical role in the physiologic regulation of vascular tone, cellular adhesion, vascular smooth muscle cell proliferation and migration, and resistance to thrombosis. VSMC, vascular smooth muscle cell. possibility of noninvasive assessment of endothelial function aiming at individualized cardiovascular medicine. This article is novel with respect to integrating current knowledge into clinical practice.
Endothelial dysfunction in coronary artery diseases
A variety of factors may damage endothelial cells, including physical injuries, biochemical injuries, and immune-mediated damage. Among them, oxidative stress is one of the most important factors that produces endothelial dysfunction through several mechanisms. Under oxidative stress, enzymatic production of ROS exceeds the available antioxidant defense systems. Initially, superoxide anions react with existing NO to produce peroxynitrite (ONOO − ), thus reducing the concentration of NO. In addition, the resulting ONOO − , which is itself strongly oxidizing, diminishes the production of NO by reducing endothelial NO synthase (eNOS) activity [15] . Mechanistically, ONOO − oxidizes tetrahydrobiopterin (BH 4 ), an essential cofactor of eNOS, to BH 3 radicals, and the resulting decrease in BH 4 is likely to be the major cause for dysfunctional eNOS, 'eNOS uncoupling'. Oxidation of BH 4 not only reduces BH 4 bioavailability, but the oxidation products such as BH 2 may compete with BH 4 for binding to NO synthase [16] . Furthermore, NO synthase itself can be a source of superoxide. Cofactors, in particular BH 4 , have a crucial role in this NO synthase-dependent ROS production. NO synthase reduces molecular oxygen levels in the absence of BH 4 , which results in further production of superoxide rather than NO [15] . Although it is still challenging to measure the levels of circulating biomarkers of oxidative stress, measurements of stable products released by the reaction of ROS and vascular/ circulating molecular structures, such as serum lipid hydroperoxides, plasma malondialdehyde, or urine F2-isoprostanes, have been reported to be a prognostic factor for cardiovascular disease [17] .
Endothelial cells are constantly exposed to these milieus and endeavor to maintain homeostasis with antithrombotic, anti-inflammatory, and antiproliferative properties [18] . Endothelial dysfunction leads to compensatory responses that alter the normal homeostatic properties of the endothelium, resulting in impairment or loss of its normal function, such as impairment of endothelium-dependent vasodilatation, the hallmark of endothelial dysfunction, because of an imbalance in the release of vasoconstrictor and vasodilator agents from the endothelium. Figure 2 shows the role of endothelial dysfunction in coronary artery diseases. Epicardial and microvascular coronary endothelial dysfunction is an independent predictor of acute cardiovascular events, irrespective of the presence or absence of angiographically detectable coronary lesions [19, 20] . Endothelial dysfunction in epicardial and/or microcirculatory coronary arteries causes myocardial ischemia [21, 22] . It is suggested that coronary microcirculatory endothelial dysfunction may be an important feature of the pathophysiology of apical ballooning syndrome [23, 24] , impaired left ventricular relaxation in patients with normal ejection fraction in the absence of occlusive coronary artery disease [25] [26] [27] , and cardiomyopathy [28] .
The process of atherosclerosis begins early in life, and endothelial dysfunction contributes to atherogenesis at every phase of atherosclerosis [29] . The earliest atherosclerotic changes take place in the endothelium before morphological plaque formation, including increased endothelial permeability to lipoproteins and other plasma constituents, and formation of specific adhesion molecules on the surface of the endothelium that are responsible for the adherence, migration, and accumulation of monocytes and T cells [30] . These adhesion molecules include vascular cell adhesion molecule 1, intracellular adhesion molecule 1, E-selectin, and P-selectin. Lipoprotein particles bind to proteoglycan in the intima and they are retained. Lipoprotein particles bound to proteoglycan have increased susceptibility to oxidative or other chemical modifications. Subsequently, in response to the oxidized low density lipoprotein cholesterol, vascular endothelial cells and smooth muscle cells secrete monocyte chemotactic protein-1 and macrophage colony-stimulating factor, which promote monocyte chemotaxis, adhesion, and differentiation into macrophages and can augment scavenger receptors [31] . These macrophages englobe and accumulate oxidized lipids. Initially, fatty steaks consist of lipid-laden monocytes and macrophages (foam cells), together with T lymphocytes. Later, smooth muscle cells migrate, and then fatty steaks are mainly formed by lipid accumulation in macrophage-derived foam cells and vascular smooth muscle cells [31] . Thus, endothelial dysfunction plays a key role in both initiation and progression of atherosclerotic plaques.
The pathological features of the most common type of vulnerable plaque include a thin fibrous cap, a large lipid pool inside the plaque, increased macrophage infiltration within the cap, and apoptosis, resulting in the growth of the necrotic core [32] . Endothelial dysfunction also has important roles in all of these features [33] . Recent clinical studies on patients with mild coronary artery disease demonstrated that coronary endothelial dysfunction was associated with vulnerable plaque characteristics including increased lipid accumulation and necrotic core formation compared with patients with normal endothelial function [34, 35] . The major mechanism of coronary thrombosis is a fracture in the protective fibrous cap of the plaque. Against the impinging forces on the plaque cap, institutional forms of collagen, such as type-I and type-III collagens, provide most of the biomechanical resistance to disruption of the fibrous cap [36] . Proinflammatory cytokines, in particular γ-interferon, induce the expression of enzymes capable of breaking down constituents of the arterial extracellular matrix [37] . In particular, matrix metalloproteinases can degrade the collagen fibrils that lend strength to the fibrous cap [33] . Impaired endothelial function is associated with an increased inflammatory response, thrombogenicity, and enhanced local expression of matrix metalloproteinases [30, 38] . Another mechanism of coronary thrombosis involves superficial erosion of the intima [39] . Although the underlying molecular mechanisms of superficial erosion remain obscure, apoptosis of endothelial cells could contribute to desquamation of endothelial cells in areas of superficial erosion [40] . Thus, impaired endothelial function initiates a cascade of events that permit atherogenesis to proceed, ultimately culminating in lesions that are likely to result in acute coronary syndromes ( Fig. 2 ). 
Assessment of endothelial function
Endothelial function can be assessed in humans by assaying the capacity of the endothelium to perform its various physiologic functions, including regulation of vasomotor tone, expression of adhesion molecules, and maintenance of an antithrombotic microenvironment. NO is an important vasodilator and is produced from L-arginine by the action of the enzyme NO synthase [41] . NO is responsible for the balance of endotheliumderived contracting factors, such as endothelin-1 and thromboxane A2, thus regulating the vascular tone. In addition, it also suppresses platelet aggregation, inflammation, oxidative stress, vascular smooth muscle cell migration and proliferation, and leukocyte adhesion [42] . Therefore, generally reducing endothelium-dependent vasodilation indicates a broadly dysfunctional phenotype across many properties of the endothelium. Thus, the assessment of vasodilator properties resulting from NO and other molecules has become the most widely used clinical endpoint for the assessment of endothelial function. Testing involves pharmacological and/or physiological stimulation of release of NO and other vasoactive substances from the endothelium by invasive and noninvasive methods.
Invasive methods
Initial clinical studies on endothelial function involved assessment of coronary circulation, and invasive assessment by cardiac catheterization is considered the reference standard for evaluating coronary endothelial function [43] . This method involves intra-arterial administration of endothelium-dependent vasodilatory substances (such as acetylcholine) with measurement of changes in vessel diameter by quantitative coronary angiography and measurement of changes in coronary blood flow by Doppler flow wire. The vasodilatory agent delivered into coronary arteries activates endothelial cells and stimulates NO release, leading to measurable vasodilatation and increase in coronary blood flow in normal individuals but vasoconstriction and lack of increase in coronary blood flow as a result of direct activation of muscarinic receptors on vascular smooth muscle cells in patients with endothelial dysfunction. In 1986, Ludmer et al. [44] first demonstrated endothelial dysfunction during the course of coronary atherosclerosis through intracoronary infusion of acetylcholine and quantitative coronary angiography, and the first evidence of the longterm prognostic significance of coronary endothelial vasodilator dysfunction on atherosclerotic disease progression and cardiovascular events was reported by Schächinger et al. [45] . Since these seminal studies, the concept that atherosclerosis is a purely structural disease has expanded to include its functional manifestations, such as paradoxical vasoconstriction as a consequence of a dysfunctional endothelium. In addition to evidence of epicardial coronary endothelial dysfunction, microvascular coronary endothelial dysfunction as assessed by coronary flow response to intracoronary acetylcholine has been reported to independently predict cardiovascular events irrespective of the presence or absence of angiographically detectable coronary lesions [19, 20] . Yoon et al. [46] recently reported a randomized study of 35 patients with nonobstructive coronary artery disease. In this study, the left anterior descending coronary artery was divided into proximal, middle, and distal segments, and interestingly, epicardial coronary endothelial function was assessed in each segment. Patients were randomized to treatment with placebo or an endothelin-A receptor antagonist, and plaque volume change was evaluated by intravascular ultrasound at baseline and at the 6-month follow-up. They demonstrated that significant plaque progression occurred in the coronary artery segments with endothelial dysfunction, but not in segments with normal endothelial function, and this plaque progression was attenuated by the endothelin-A receptor antagonist, indicating the important role of coronary endothelial dysfunction in coronary artery disease progression. However, the undeniable disadvantage with such a method is its invasive and costly nature; therefore, its widespread use and clinical utility are limited.
Noninvasive methods
Recently, several noninvasive methods for the assessment of endothelial function have been introduced. As endothelial dysfunction is a systemic process, these techniques are based on the diffuse and systemic nature of endothelial dysfunction. Most of the methods to evaluate peripheral endothelial function are grounded on the same principlethat is, of reactive hyperemia, which serves as an index of endothelium-dependent vasodilator function ( Fig. 3 ). Evaluation of forearm flow-mediated vasodilatation (FMD) is one of these methods, and its measures correlate well with coronary artery endothelial function as assessed by catheterization [47] . To evaluate endothelium-dependent dilation capacity, the diameter of the brachial artery proximal to the antecubital fossa is measured at rest and during reactive hyperemia, which is achieved by rapid release of a pneumatic pressure cuff placed around the forearm and inflated to suprasystolic pressure for 5 min. Another major noninvasive method to assess peripheral endothelial function, based on the same principle, is reactive hyperemia-peripheral arterial tonometry (RH-PAT) [2, 48] . Peripheral arterial tonometry probes are placed on one finger of each hand and the pulse wave amplitude is assessed before and during reactive hyperemia. RH-PAT technology enables beatto-beat plethysmographic recording of the finger arterial pulse wave amplitude, which is a measure of pulsatile volume changes, and its response is also well correlated with coronary artery endothelial dysfunction [48] . The majority of the noninvasive peripheral endothelial function tests use reactive hyperemia after occlusion as a trigger to detect endothelium-dependent vasodilation; however, FMD represents conduit artery vasodilation, whereas RH-PAT represents microvessel vasodilation. A main advantage of the RH-PAT technique is that the contralateral arm serves as its internal control, which can be used to correct for any systemic changes during the test, in contrast to FMD. Moreover, the RH-PAT technique is easy to use and operator independent.
Prognostic value of noninvasive endothelial function testing in primary and secondary prevention settings Several previous studies have reported the additional value of noninvasive endothelial function assessment in predicting cardiovascular events in primary prevention settings. In one study of 435 and one study of 618 middle-aged healthy individuals without heart disease and with low clinical risk, brachial artery FMD independently predicted cardiovascular events, in addition to traditional risk factors, over an average follow-up 2.7 and 4.6 years [8, 49] . In a similar study with 270 middle-aged low-risk individuals followed up for 7 years, endothelial dysfunction as assessed by RH-PAT significantly predicted adverse cardiovascular events independent from traditional Framingham Risk Score [9] . In addition, the ability of endothelial function to predict cardiovascular events was assessed in the elderly. The Cardiovascular Health Study, which included 2792 apparently healthy older adults aged between 72 and 98 years, investigated the relationship between peripheral endothelial function and subsequent cardiovascular events over a 5-year follow-up period, and demonstrated that peripheral endothelial function is a significant predictor of future cardiovascular events even after adjustment for traditional risk factors [10] . In the Multiethnic Study of Atherosclerosis [11] , 3026 individuals free from known atherosclerotic cardiovascular disease were enrolled. Importantly, this study sample included 34% white, 20% Chinese, 21% Black, and 25% Hispanic individuals. In this population-based cohort study, peripheral endothelial function assessment in addition to Framingham Risk Score assessment improved the risk classification for future cardiovascular events. Furthermore, it is worthy to note that a study that included 400 postmenopausal hypertensive women without evidence of coronary artery disease demonstrated that endothelial function significantly improved after 6 months of antihypertensive therapy, and improvement in endothelial function clearly identified patients who possibly have a more favorable prognosis [13] . In this study, women whose endothelial function had not improved 6 months after optimal treatment of blood pressure showed a nearly seven-fold increase in the risk for cardiovascular events over an average follow-up of 67 months.
Coronary endothelial dysfunction seems to be present in most of the patients with coronary artery disease, and it is reversible [50] . In the setting of established coronary artery disease, patients with endothelial dysfunction have higher rates of adverse cardiovascular events compared with those with normal endothelial function [51] , and impaired peripheral endothelial function has been shown to be an independent predictor of cardiovascular events among patients with established coronary artery disease.
In a study of 281 stable patients with documented coronary artery disease, endothelial dysfunction predicted the risk for cardiovascular events independent from traditional risk factors, over a mean follow-up of 4.5 years [52] . In addition, in another study of patients with angiographically documented acute coronary syndrome [53] , endothelial function was assessed before hospital discharge, within 5 days of an episode of acute coronary syndrome. Impaired endothelial function was associated with future cardiovascular events. It is noteworthy that endothelial function was reassessed 8 weeks after an episode of acute coronary syndrome, and improvement in endothelial function was significantly associated with fewer future cardiovascular events. A previous report documented that the overall survival in patients with coronary artery disease is largely independent of the degree of coronary luminal stenosis [54] . Furthermore, it was reported that, in patients with coronary artery disease, impaired peripheral endothelial function significantly predicts future cardiovascular events independent from coronary plaque complexity, as assessed using the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) Score [55] . Importantly, even in patients with coronary artery disease, the improvement of peripheral endothelial function is associated with a significant reduction in future cardiovascular events [12, 53] .
Taken together, the utility of peripheral endothelial function, as assessed by noninvasive methods, in predicting cardiovascular events in both primary and secondary prevention settings has been demonstrated in several studies and meta-analyses [8, 10, 11, 13, [56] [57] [58] [59] . In addition, it is noteworthy that, as mentioned above, patients whose peripheral endothelial dysfunction does not improve through interventions might be at a higher risk for future events compared with those with improvement in endothelial dysfunction, in both primary and secondary prevention settings.
Therapeutic approaches
Pharmacologic treatment of specific risk factors and lifestyle modifications, such as smoking cessation, weight loss, diet change, and exercise, are reportedly effective in preventing atherosclerotic diseases. Furthermore, pharmacological interventions in atherosclerotic diseases have advanced markedly over the decades. However, clinical management of atherosclerosis is still quite difficult as there is no recognized method to prevent atherosclerosis or improve the entire vascular bed. dysfunction by interventions with risk reduction for future cardiovascular events in primary and secondary prevention settings [12, 13] . Thus, it is probably a good prognostic sign when endothelial dysfunction is reversed with treatments. In addition, most intervention studies reporting effects on cardiovascular risk factors also show consistent results with regard to endothelial function and cardiovascular outcomes ( Table 2) . Clinical guidelines recommend (a) moderate-intensity aerobic activity, (b) weight loss, (c) smoking cessation, (d) use of angiotensin converting enzyme inhibitors (ACEIs), (e) use of statins, and (f) use of β-blockers, which are clearly supported by clinical evidence [60] . The effect of each intervention on endothelial function is listed below.
Physical activity
A recent meta-analysis provided evidence that physical activity improves endothelial function in individuals at an increased cardiovascular risk [61] . In addition, a metaanalysis of patients with type 2 diabetes mellitus also reported a beneficial effect of increasing physical activity on endothelial function [62] . A study of 43 obese patients demonstrated that exercise training improved RH-PAT, and an improvement in insulin resistance was independently correlated with an improvement in endothelial function [63] .
Weight loss
Several intervention studies have investigated short-term and long-term effects of weight loss on endothelial function and have suggested that endothelial dysfunction could be reversed by medical and surgical weight loss [64] [65] [66] . One study with 29 severely obese participants (BMI 48 9 kg/m 2 ) reported that long-term sustained weight loss significantly improved endothelial dysfunction at 1 year [66] . In another study with 41 obese patients, 17 patients were treated with medical therapy alone and 24 patients underwent gastric bypass surgery [64] . Gastric bypass surgery was associated with more marked weight loss, greater metabolic changes, and more pronounced improvement in endothelial function compared with medical therapy alone. In contrast, a study of 70 Japanese patients with metabolic syndrome (BMI 26 4 kg/m 2 , waist 93 7 cm in male and 96 11 cm in female patients) demonstrated that a reduction in waist circumference, rather than a reduction in BMI, was associated with improvement in endothelial function [14] .
Smoking cessation
In 1993, Celermajer et al. [67] reported that cigarette smoking is associated with dose-related and potentially reversible impairment of endothelial function. Furthermore, in 1996, passive smoking was also reported to be associated with dose-related endothelial dysfunction [68] .
In a recent prospective study of 1504 current smokers [69] , smoking intensity was found to be independently associated with endothelial dysfunction at baseline. Despite the fact that BMI and waist circumference increased after smoking cessation, endothelial function significantly improved after 1 year among those who had quit smoking; however, it did not change among those who continued to smoke.
Angiotensin converting enzyme inhibitors
ACEIs improve endothelial function by reducing the production of angiotensin II by inhibiting angiotensin converting enzyme, a key enzyme affecting the transformation from angiotensin I to angiotensin II and increasing bradykinin production [70, 71] . A meta-analysis of randomized controlled trials showed that ACEIs improve peripheral endothelial function and are superior to other antihypertensive drugs including calcium channel blockers and β-blockers [72] .
Statins
The beneficial effect of statins on endothelial function, in addition to lowering cholesterol levels, is attributed partly to their anti-inflammatory and antioxidant properties [73] . The significant beneficial effect of statin therapy on endothelial function in coronary and peripheral arteries was demonstrated by a recent meta-analysis of 46 randomized clinical trials [74] .
β-blockers
First-and second-generation β-blockers have no significant effect on endothelial function. However, a different efficacy has been suggested for the thirdgeneration β-blockers, such as nebivolol and carvedilol. Both drugs have been reported to improve endothelial function, which is mediated by β3-receptor activation by nebivolol and the antioxidant effect of carvedilol [75, 76] .
A recent randomized controlled study reported that carvedilol was able to improve endothelial function compared with metoprolol in patients with hypertension and diabetes mellitus [77] .
In addition to the above, obstructive sleep apnea syndrome is associated with endothelial dysfunction and its severity is related to the degree of endothelial dysfunction [78] . Continuous positive airway pressure therapy may improve cardiovascular outcomes [79, 80] , and some small clinical studies have reported the beneficial effects of treatment of obstructive sleep apnea on endothelial dysfunction [81, 82] . Evidence of the efficacy of blood glucose lowering therapy on cardiovascular disease outcomes from large clinical trials is conflicting [83] . Consistently, it was reported that brachial artery endothelial function was not influenced by reduction in hemoglobin A1c levels [84] .
Fluctuations in blood glucose levels, rather than hemoglobin A1c levels, might have an important role in endothelial dysfunction in type 2 diabetes [85] . Similarly, the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE) study reported increased risk for cardiovascular events and mortality among patients treated with torcetrapib, the cholesterol ester transfer protein inhibitor [86] , and it is suggested that sustained and marked impairment of endothelial function may at least in part explain the increased mortality associated with torcetrapib treatment in the trial [87] .
These indicate that a clinical strategy with endothelial function assessment is potentially useful in improving cardiovascular disease outcomes. Assessment of endothelial function may allow us to treat atherosclerosis itself, rather than controlling its risk factors. Lifestyle modification Figure 4 shows a potential strategy for cardiovascular disease prevention with endothelial function assessment.
As demonstrated by the studies discussed in the current review, noninvasive endothelial function assessment has several advantages, and it seems to be feasible and reasonable to manage patients according to the endothelial function-guided strategy. However, there are still several points of controversy (Table 3 ). For example, data indicate the significant predictive value of endothelial function for future cardiovascular events in addition to traditional risk factors; nonetheless, endothelial function measurements are not yet recommended by the latest guidelines for risk assessment [6] . This might be attributed to the poorly standardized methodology of noninvasive endothelial function assessment. With technical modifications and more accurate analysis software, the variability in FMD measurements and thus the specificity can be further improved. The methodology of RH-PAT measurement is well standardized, and this technique has the advantage of the automatic and operatorindependent feature. However, evidence on the utility of RH-PAT is still scarce. Although, the endothelial function-guided prevention strategy, with pharmacological therapies, lifestyle modification, etc., might be beneficial in providing tailored treatment according to the specificities of atherosclerosis in a given patient, we cannot draw a definite conclusion as yet; therefore, the question of whether endothelial function-guided therapies will provide benefits with regard to improving outcomes in patients with risk factors and in patients with established atherosclerotic cardiovascular disease should be tested in large-scale randomized studies.
Thus, current evidence in this area is definitely not enough to establish the endothelial function-based prevention strategy. Further evidence is required to determine appropriate participants for endothelial function testing, a standardized method, a reference value, and a proper frequency of tests, in addition to verification of the benefit of the endothelial function-guided strategy ( Table 3) . Such studies may lead us into a new era of individualized medicine based on endothelial function assessment in cardiology.
Summary
Although progress in the modification of conventional coronary risk factors and lifestyle behavior reduced atherosclerotic coronary artery disease incidence, it continues to be one of the most common causes of death and disability in the USA and the developed world. This might be attributed to the defective current risk stratifying and prevention strategies for coronary artery disease. In the current clinical settings, atherosclerotic cardiovascular disease risk is estimated by identifying and quantifying the traditional risk factors, and nontraditional risk factors are not considered. Thus, the current patientspecific risk assessment may be insufficient to identify individual risk. In addition, most of the prevailing therapies are targeted toward traditional risk factors rather than atherosclerosis itself.
Endothelial function is an integrated index of all atherogenic and atheroprotective factors present in an individual, including nontraditional and unknown factors, and it, in addition to traditional risk factors, has a significant predictive value for future cardiovascular events. Moreover, endothelial function has a pivotal role in all phases of atherosclerosis, from initiation to atherothrombotic complication, and is reversible at every phase, indicating the utility of endothelial function-guided therapies. Further research, including large-scale randomized controlled trials, is necessary to determine whether noninvasive endothelial function assessment can be useful in guiding treatment and changing outcomes. A standardized method and a reference value How often?
A proper frequency How effective?
Effectiveness of endothelial function-guided strategy
